Monthly Archives: September 2012

The lack of robust reproducibility in the scientific literature is both shocking and troubling, and has been a widely covered topic over the past couple years. One of the earliest blogs here at LifeSciVC was on the dirty secret that

Not a biotech conference goes by these days without a discussion about new models for financing or exiting companies, and BioPharm America in Boston this week is no different.  I’m on a panel discussing the topic on Wednesday afternoon. New

Earnout deals are back in the news with an interesting report from Shareholder Representative Services, or SRS, a firm who specializes in working for the selling party’s shareholders to follow up post-acquisition to ensure that escrows are paid, diligence is

Almost every biotech has a Scientific Advisory Board, but few use them particularly well.   Although SABs can be hugely valuable in helping shape a program or portfolio, or raising the visibility of a startup, they can also be a colossal